Hypertonie bei Dialysepatienten

ZUSAMMENFASSUNG

Die Hypertonie bei Dialysepatienten ist eine besondere Herausforderung, die zuletzt durch eine uneinheitliche Definition verkompliziert wurde. Eine optimale Hypertoniekontrolle wird bisher nur bei wenigen Patienten erreicht. Therapeutisch sollten primär nicht pharmakologische Maßnahmen ergriffen werden, hierbei dient der Salz- und Volumenstatus als zentraler und fundamentaler Angriffspunkt. Eine medikamentöse Therapie scheint sich positiv auf die kardiovaskuläre Prognose auszuwirken; eine überlegene Substanz als primäre Wahl konnte jedoch bisher noch nicht eindeutig identifiziert werden. Zukünftig braucht es mehr Studien, um Ziel-Blutdruck-Werte festlegen zu können und die Wirksamkeit von nicht medikamentösen und medikamentösen Maßnahmen hinsichtlich der kardiovaskulären Prognose zu überprüfen.

• Literatur

• 1 Sarafidis PA, Persu A, Agarwal R. et al. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). Nephrol Dial Transplant 2017; 32: 620-640 doi:10.1093/ndt/gfw433
• 2 Siu AL. U. S. Preventive Services Task Force. Screening for high blood pressure in adults: U. S. Preventive Services Task Force recommendation statement. Ann Intern Med 2015; 163: 778-786 doi:10.7326/M15-2223
• 3 Agarwal R, Light RP. Chronobiology of arterial hypertension in hemodialysis patients: implications for home blood pressure monitoring. Am J Kidney Dis 2009; 54: 693-701 doi:10.1053/j.ajkd.2009.03.018
• 4 Agarwal R, Andersen MJ, Light RP. Location not quantity of blood pressure measurements predicts mortality in hemodialysis patients. Am J Nephrol 2008; 28: 210-217 doi:10.1159/000110090
• 5 Kidney Disease Outcomes Quality Initiative (K/DOQI) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 (Suppl. 01) S1-S290
• 6 Agarwal R, Peixoto AJ, Santos SF, Zoccali C. Pre- and postdialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure. Clin J Am Soc Nephrol 2006; 1: 389-398 doi:10.2215/CJN.01891105
• 7 Kelley K, Light RP, Agarwal R. Trended cosinor change model for analyzing hemodynamic rhythm patterns in hemodialysis patients. Hypertension, 2007; 50: 143-150 doi:10.1161/HYPERTENSIONAHA.107.091579
• 8 Zucchelli P, Santoro A, Zuccala A. Genesis and control of hypertension in hemodialysis patients. Semin Nephrol 1988; 8: 163-168
• 9 Günal AI, Duman S, Ozkahya M. et al. Strict volume control normalizes hypertension in peritoneal dialysis patients. Am J Kidney Dis 2001; 37: 588-593
• 10 Agarwal R, Alborzi P, Satyan S, Light RP. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension 2009; 53: 500-507 doi:10.1161/HYPERTENSIONAHA.108.125674
• 11 Dahlmann A, Dorfelt K, Eicher F. et al. Magnetic resonance-determined sodium removal from tissue stores in hemodialysis patients. Kidney Int 2015; 87: 434-441 doi:10.1038/ki.2014.269
• 12 Agarwal R, Light RP. Arterial stiffness and interdialytic weight gain influence ambulatory blood pressure patterns in hemodialysis patients. Am J Physiol Renal Physiol 2008; 294: F303-F308 doi:10.1152/ajprenal.00575.2007
• 13 Georgianos PI, Sarafidis PA, Lasaridis AN. Arterial stiffness: a novel cardiovascular risk factor in kidney disease patients. Curr Vasc Pharmacol 2015; 13: 229-238
• 14 Daugirdas JT, Blake PG, Ing TS. Handbook of dialysis. 5th ed. Philadelphia: Wolters Kluwer Health; 2015
• 15 Hausberg M, Kosch M, Harmelink P. et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106: 1974-1979
• 16 Tada T, Kusano KF, Ogawa A. et al. The predictors of central and obstructive sleep apnoea in haemodialysis patients. Nephrol Dial Transplant, 2007; 22: 1190-1197 doi:10.1093/ndt/gfl748
• 17 Kornerup HJ, Schmitz O, Danielsen H. et al. Significance of the renin-angiotensin system for blood pressure regulation in end-stage renal disease. Contrib Nephrol 1984; 41: 123-127
• 18 Henrich WL, Katz FH, Molinoff PB, Schrier RW. Competitive effects of hypokalemia and volume depletion on plasma renin activity, aldosterone and catecholamine concentrations in hemodialysis patients. Kidney Int 1977; 12: 279-284
• 19 Vallance P, Leone A, Calver A. et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575
• 20 Del Vecchio L, Locatelli F. An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease. Expert Opin Drug Saf 2016; 15: 1021-1030 doi:10.1080/14740338.2016.1182494
• 21 Smyth B, Jones C, Saunders J. Prescribing for patients on dialysis. Aust Prescr 2016; 39: 21-24 doi:10.18773/austprescr.2016.008
• 22 George J, Majeed W, Mackenzie IS. et al. Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study. BMJ 2013; 347: f6954 doi:10.1136/bmj.f6954
• 23 Sarafidis PA, Sharpe CC, Wood E. et al. Prevalence, patterns of treatment, and control of hypertension in predialysis patients with chronic kidney disease. Nephron Clin Pract 2012; 120: c147-c155 doi:10.1159/000337571
• 24 Agarwal R, Nissenson AR, Batlle D. et al. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003; 115: 291-297
• 25 Agarwal R. Epidemiology of interdialytic ambulatory hypertension and the role of volume excess. Am J Nephrol 2011; 34: 381-390 doi:10.1159/000331067
• 26 Takeda A, Toda T, Fujii T. et al. Discordance of influence of hypertension on mortality and cardiovascular risk in hemodialysis patients. Am J Kidney Dis 2005; 45: 112-118
• 27 Heerspink HJ, Ninomiya T, Zoungas S. et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009; 373: 1009-1015 doi:10.1016/S0140-6736(09)60212-9
• 28 Foley RN, Parfrey PS, Kent GM. et al. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 2000; 11: 912-916
• 29 Agarwal R. How should hypertension be assessed and managed in hemodialysis patients? Home BP, not dialysis unit BP, should be used for managing hypertension. Semin Dial 2007; 20: 402-405 doi:10.1111/j.1525-139X.2007.00314.x
• 30 Stack AG, Molony DA, Rives T. et al. Association of physical activity with mortality in the US dialysis population. Am J Kidney Dis 2005; 45: 690-701
• 31 Sinha AD, Agarwal R. Can chronic volume overload be recognized and prevented in hemodialysis patients? The pitfalls of the clinical examination in assessing volume status. Semin Dial 2009; 22: 480-482 doi:10.1111/j.1525-139X.2009.00641.x
• 32 Raimann J, Liu L, Tyagi S. et al. A fresh look at dry weight. Hemodial Int 2008; 12: 395-405 doi:10.1111/j.1542-4758.2008.00302.x
• 33 Movilli E, Gaggia P, Zubani R. et al. Association between high ultrafiltration rates and mortality in uraemic patients on regular haemodialysis. A 5-year prospective observational multicentre study. Nephrol Dial Transplant 2007; 22: 3547-3552 doi:10.1093/ndt/gfm466
• 34 Agarwal R, Sinha AD, Pappas MK. et al. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant 2014; 29: 672-681 doi:10.1093/ndt/gft515
• 35 Cice G, Ferrara L, D’Andrea A. et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. Journal of the American College of Cardiology 2003; 41: 1438-1444
• 36 Tepel M, Hopfenmueller W, Scholze A. et al. Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transplant, 2008; 23: 3605-3612 doi:10.1093/ndt/gfn304
• 37 Kungys G, Naujoks H, Wanner C. Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. Eur J Clin Pharmacol 2003; 59: 291-295 doi:10.1007/s00228-003-0620-4
• 38 Weir MA, Fleet JL, Dixon SN. et al. Angiotensin Converting Enzyme Inhibitor Dialyzability and Outcomes in Older Patients Receiving Hemodialysis. Blood Purif, 2015; 40: 232-242 doi:10.1159/000438821
• 39 Weir MA, Dixon SN, Fleet JL. et al. β-Blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc Nephrol 2015; 26: 987-996 doi:10.1681/ASN.2014040324